All In Biotech

Drug Trial Radar · NCT05934331

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of the LM-302 Combination With Other Anti-tumor Treatment in Subjects With CLDN18.2-positive Advanced Gastro-Intestinal Cancer.

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

632

Planned (sponsor's estimate)

Start

Jul 27, 2023

Primary completion

Aug 6, 2031

Study completion Aug 6, 2031

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.

Conditions

  • Malignant Neoplasms of Digestive Organs

Interventions

  • LM-302Drug

    Q2W/Q3W,Administered intravenously

  • ToripalimabDrug

    Q2W/Q3W,Administered intravenously

  • CapecitabineDrug

    BID,Oral Administration

  • Tegafur, Gimeracil and Oteracil Potassium CapsulesDrug

    BID,Oral Administration

  • NivolumabDrug

    Q4W,Administered intravenously

  • ApatinibDrug

    QD,Oral Administration

  • GemcitabineDrug

    Q4W,Administered intravenously

  • TislelizumabDrug

    Q2W Administered intravenously

  • AnlotinibDrug

    QD,Oral Administration

  • BenmelstobartDrug

    Q4W Administered intravenously

  • LM-302Drug

    Q2W Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 112 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.